Personalizing tacrolimus dosing after kidney transplant
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study looks at how well tacrolimus, a medicine that prevents kidney rejection, works in people after a kidney transplant. By checking your immune system and your medicine levels, the goal is to find the best dose for each person to keep your new kidney healthy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You had a kidney transplant for the first time
- You are taking the anti-rejection medicine tacrolimus and have records of your doses and blood tests
- You can be followed at this center for at least 12 months
- You are willing to give written consent to participate
- You did not have a combined transplant, and you do not have active infections or serious liver or kidney disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether doing a simple genetic test before starting the anti-rejection drug tacrolimus can lead to better dosing and outcomes in kidney transplant patients. It also looks at whether this approach is cost-effective.
This study tests a personalized approach to dosing tacrolimus (an anti-rejection medicine) in children who have had a kidney transplant. By using each child's own data, doctors hope to find the best dose to keep the transplanted kidney healthy and avoid side effects.
This study looks at how tacrolimus (a rejection-preventing medicine) should be dosed in the first days to years after a kidney transplant. It may help personalize dosing by comparing different patient groups, including using genetic testing.
This trial tests whether safely lowering the dose of tacrolimus—an anti-rejection drug—can still protect a kidney transplant one year after surgery. It's for first-time transplant recipients with low immune risk.
This trial tests a new way to personalize tacrolimus dosing for children after a kidney, liver, or heart transplant. It uses genetic information and a formula to find the best starting dose, aiming to improve outcomes.
This study tests whether giving tacrolimus at a time of day matched to each patient's body clock can improve safety and effectiveness after a kidney transplant. It may help recipients maintain stable drug levels with fewer side effects.
Hear when a new Transplant Recipient (Kidney) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.